| Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma TS Mok, YL Wu, S Thongprasert, CH Yang, DT Chu, N Saijo, ... New England Journal of Medicine 361 (10), 947-957, 2009 | 10239 | 2009 |
| Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open … C Zhou, YL Wu, G Chen, J Feng, XQ Liu, C Wang, S Zhang, J Wang, ... The lancet oncology 12 (8), 735-742, 2011 | 5059 | 2011 |
| Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer AT Shaw, DW Kim, K Nakagawa, T Seto, L Crinó, MJ Ahn, T De Pas, ... New England Journal of Medicine 368 (25), 2385-2394, 2013 | 4027 | 2013 |
| The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer P Goldstraw, K Chansky, J Crowley, R Rami-Porta, H Asamura, ... Journal of Thoracic Oncology 11 (1), 39-51, 2016 | 3974 | 2016 |
| First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer BJ Solomon, T Mok, DW Kim, YL Wu, K Nakagawa, T Mekhail, E Felip, ... New England Journal of Medicine 371 (23), 2167-2177, 2014 | 3666 | 2014 |
| Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer TS Mok, YL Wu, MJ Ahn, MC Garassino, HR Kim, SS Ramalingam, ... New England Journal of Medicine 376 (7), 629-640, 2017 | 3361 | 2017 |
| Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label … TSK Mok, YL Wu, I Kudaba, DM Kowalski, BC Cho, HZ Turna, G Castro, ... The Lancet 393 (10183), 1819-1830, 2019 | 3062 | 2019 |
| Lung cancer: current therapies and new targeted treatments FR Hirsch, GV Scagliotti, JL Mulshine, R Kwon, WJ Curran, YL Wu, ... The Lancet 389 (10066), 299-311, 2017 | 2805 | 2017 |
| Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open … YL Wu, C Zhou, CP Hu, J Feng, S Lu, Y Huang, W Li, M Hou, JH Shi, ... The lancet oncology 15 (2), 213-222, 2014 | 2430 | 2014 |
| Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised … JCH Yang, YL Wu, M Schuler, M Sebastian, S Popat, N Yamamoto, ... The lancet oncology 16 (2), 141-151, 2015 | 1864 | 2015 |
| Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically … M Fukuoka, YL Wu, S Thongprasert, P Sunpaweravong, SS Leong, ... Journal of clinical oncology 29 (21), 2866-2874, 2011 | 1843 | 2011 |
| Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study T Ciuleanu, T Brodowicz, C Zielinski, JH Kim, M Krzakowski, E Laack, ... The Lancet 374 (9699), 1432-1440, 2009 | 1820* | 2009 |
| Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial ES Kim, V Hirsh, T Mok, MA Socinski, R Gervais, YL Wu, LY Li, ... The Lancet 372 (9652), 1809-1818, 2008 | 1737 | 2008 |
| Osimertinib in Resected EGFR-Mutated Non–Small-Cell Lung Cancer YL Wu, M Tsuboi, J He, T John, C Grohe, M Majem, JW Goldman, ... New England Journal of Medicine 383 (18), 1711-1723, 2020 | 1340 | 2020 |
| Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC AB Turke, K Zejnullahu, YL Wu, Y Song, D Dias-Santagata, E Lifshits, ... Cancer cell 17 (1), 77-88, 2010 | 1224 | 2010 |
| First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study JC Soria, DSW Tan, R Chiari, YL Wu, L Paz-Ares, J Wolf, SL Geater, ... The Lancet 389 (10072), 917-929, 2017 | 1210 | 2017 |
| Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial YL Wu, Y Cheng, X Zhou, KH Lee, K Nakagawa, S Niho, F Tsuji, R Linke, ... The Lancet Oncology 18 (11), 1454-1466, 2017 | 1134 | 2017 |
| Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3 … JCH Yang, LV Sequist, SL Geater, CM Tsai, TSK Mok, M Schuler, ... The lancet oncology 16 (7), 830-838, 2015 | 966 | 2015 |
| Potential predictive value of TP53 and KRAS mutation status for response to PD-1 blockade immunotherapy in lung adenocarcinoma ZY Dong, WZ Zhong, XC Zhang, J Su, Z Xie, SY Liu, HY Tu, HJ Chen, ... Clinical cancer research 23 (12), 3012-3024, 2017 | 845 | 2017 |
| First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open … YL Wu, C Zhou, CK Liam, G Wu, X Liu, Z Zhong, S Lu, Y Cheng, B Han, ... Annals of oncology 26 (9), 1883-1889, 2015 | 796 | 2015 |
An ShejuanNorthwestern UniversityVerified email at northwestern.edu
